Meeting
2018 ASCO Annual Meeting
Determining the sensitivity of primary acute myeloid leukemia (AML) samples with FLT3-ITD or FLT3-D835 mutations to FLT3 inhibitors using an ex vivo drug sensitivity screen.
Authors
Mara Rosenberg
Oregon Health & Science University, Portland, OR
Mara Rosenberg , Guang Fan , Kevin Watanabe-Smith , Cristina Tognon , Brian J. Druker , Jeffrey Tyner , Marc Loriaux
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Track
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Sub Track
Acute Leukemia
Citation
J Clin Oncol 36, 2018 (suppl; abstr 7025)
DOI
10.1200/JCO.2018.36.15_suppl.7025
Abstract #
7025
Poster Bd #
85
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Clinical and molecular characteristics of patients with AML with an exceptional response to ivosidenib.
First Author: Justin M. Watts
Poster
2021 ASCO Annual Meeting
TP53/NPM1-mutated acute myeloid leukemia as a molecularly distinct disease entity.
First Author: Frank J Scarpa
Poster
2024 ASCO Annual Meeting
Meta-analysis of mutational site-specificity and concordance/discordance characteristics of myeloid sarcoma.
First Author: Jeff Justin Aguilar
Poster
2022 ASCO Annual Meeting
V-FAST master trial: Preliminary results of treatment with CPX-351 plus midostaurin in adults with newly diagnosed FLT3-mutated acute myeloid leukemia.
First Author: James K. McCloskey